Smith & Nephew plc Share Price and Company Fundamentals
Last traded: Last Friday at 4:05 PM
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.
|Industry / Sector||Medical Devices / Healthcare|
|Full time employees||18000|
|Mailing address||Building 5 Croxley Park Hatters Lane Watford WD18 8YE United Kingdom|
|Phone / Fax||44 1923 477 100 /|
5Y Avg. yield
Smith & Nephew plc paid £0.38 dividend and the ex-dividend date was 30 Sept 2021.The dividend payout ratio is 58.77%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.SN dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
SN's forward dividend amount is £0.27 and the forward dividend yield is 2.03%. A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.
As of Sep 2021, following are the company executives and directors listed on Smith & Nephew plc.
|Mr. Roland D. Diggelmann||CEO & Director||53||1.7M|
|Ms. Anne-Francoise Nesmes||CFO & Exec. Director||48||799.64k|
|Mr. Andrew Swift||VP of Investor Relations|
|Ms. Catheryn O'Rourke||Chief Legal & Compliance Officer||47|
|Mr. Joe Metzger||Sr. VP of Marketing Services & Communications|
|Ms. Elga Lohler||Chief HR Officer||52|
|Mr. Philip G. Cowdy||Chief Bus. Devel. & Corp. Affairs Officer||53|
|Mr. Bradley Cannon||Pres of Sports Medicine & ENT||52|
|Dr. Vasant Padmanabhan||Pres of R&D||53|
|Steve Kane||Head of HR for the US, Global Marketing and Global R&D|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Smith & Nephew plc is 11.68B and its enterprise value is 13.82B. The enterprise value to revenue ratio of SN is 2.70.
The SN's stocks Beta value is 0.45 making it 55% less volatile compared to LSE market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Smith & Nephew plc (LSE:SN) Frequently Asked Questions
1. What is Smith & Nephew plc's Stock Symbol?
Smith & Nephew plc trades on LSE under the ticker symbol "SN".
2. What is Smith & Nephew plc's stock price today?
One share of SN stock can currently be purchased for approximately £1328.5.
3. How can I contact Smith & Nephew plc?
Smith & Nephew plc's mailing address is Building 5 Croxley Park Hatters Lane Watford WD18 8YE United Kingdom. The company can be reached via phone at 44 1923 477 100.
4. What is Smith & Nephew plc's official website?
The official website of Smith & Nephew plc is http://www.smith-nephew.com.